Literature DB >> 29748442

NPM1 mutation is not associated with prolonged complete remission in acute myeloid leukemia patients treated with hypomethylating agents.

Pedro Henrique Prata1, Cécile Bally1, Thomas Prebet2, Christian Recher3, Geoffroy Venton4, Xavier Thomas5, Emmanuel Raffoux1, Arnaud Pigneux6, Thomas Cluzeau7, Judith Desoutter8, Julie Gay9, Claude Preudhomme10, Pierre Fenaux11, Lionel Adès12.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29748442      PMCID： PMC6165814          DOI： 10.3324/haematol.2018.189886

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  Molecular prognostic factors in acute myeloid leukemia receiving first-line therapy with azacitidine.

Authors:  J Desoutter; J Gay; C Berthon; L Ades; B Gruson; S Geffroy; I Plantier; A Marceau; N Helevaut; J Fernandes; M Bemba; L Stalnikiewicz; C Frimat; J Labreuche; O Nibourel; C Roumier; M Figeac; P Fenaux; B Quesnel; A Renneville; A Duhamel; C Preudhomme
Journal:  Leukemia       Date:  2015-11-19       Impact factor: 11.528

2.  Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.

Authors:  Pierre Fenaux; Ghulam J Mufti; Eva Hellström-Lindberg; Valeria Santini; Norbert Gattermann; Ulrich Germing; Guillermo Sanz; Alan F List; Steven Gore; John F Seymour; Hervé Dombret; Jay Backstrom; Linda Zimmerman; David McKenzie; C L Beach; Lewis R Silverman
Journal:  J Clin Oncol       Date:  2009-12-21       Impact factor: 44.544

3.  Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).

Authors:  Christian Thiede; Sina Koch; Eva Creutzig; Christine Steudel; Thomas Illmer; Markus Schaich; Gerhard Ehninger
Journal:  Blood       Date:  2006-02-02       Impact factor: 22.113

4.  International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.

Authors:  Hervé Dombret; John F Seymour; Aleksandra Butrym; Agnieszka Wierzbowska; Dominik Selleslag; Jun Ho Jang; Rajat Kumar; James Cavenagh; Andre C Schuh; Anna Candoni; Christian Récher; Irwindeep Sandhu; Teresa Bernal del Castillo; Haifa Kathrin Al-Ali; Giovanni Martinelli; Jose Falantes; Richard Noppeney; Richard M Stone; Mark D Minden; Heidi McIntyre; Steve Songer; Lela M Lucy; C L Beach; Hartmut Döhner
Journal:  Blood       Date:  2015-05-18       Impact factor: 22.113

5.  Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report.

Authors:  Fabiana Ostronoff; Megan Othus; Michelle Lazenby; Elihu Estey; Frederick R Appelbaum; Anna Evans; John Godwin; Amanda Gilkes; Kenneth J Kopecky; Alan Burnett; Alan F List; Min Fang; Vivian G Oehler; Stephen H Petersdorf; Era L Pogosova-Agadjanyan; Jerald P Radich; Cheryl L Willman; Soheil Meshinchi; Derek L Stirewalt
Journal:  J Clin Oncol       Date:  2015-02-23       Impact factor: 44.544

6.  Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.

Authors:  Susanne Schnittger; Claudia Schoch; Wolfgang Kern; Cristina Mecucci; Claudia Tschulik; Massimo F Martelli; Torsten Haferlach; Wolfgang Hiddemann; Brunangelo Falini
Journal:  Blood       Date:  2005-08-02       Impact factor: 22.113

Review 7.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

8.  Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy.

Authors:  Naval Daver; Theresa Liu Dumlao; Farhad Ravandi; Sherry Pierce; Gautam Borthakur; Naveen Pemmaraju; Aziz Nazha; Stefan Faderl; Elias Jabbour; Guillermo Garcia-Manero; Jorges Cortes; Hagop Kantarjian; Alfonso Quintás-Cardama
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-06-10

9.  TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Authors:  John S Welch; Allegra A Petti; Christopher A Miller; Catrina C Fronick; Michelle O'Laughlin; Robert S Fulton; Richard K Wilson; Jack D Baty; Eric J Duncavage; Bevan Tandon; Yi-Shan Lee; Lukas D Wartman; Geoffrey L Uy; Armin Ghobadi; Michael H Tomasson; Iskra Pusic; Rizwan Romee; Todd A Fehniger; Keith E Stockerl-Goldstein; Ravi Vij; Stephen T Oh; Camille N Abboud; Amanda F Cashen; Mark A Schroeder; Meagan A Jacoby; Sharon E Heath; Kierstin Luber; Megan R Janke; Andrew Hantel; Niloufer Khan; Madina J Sukhanova; Randall W Knoebel; Wendy Stock; Timothy A Graubert; Matthew J Walter; Peter Westervelt; Daniel C Link; John F DiPersio; Timothy J Ley
Journal:  N Engl J Med       Date:  2016-11-24       Impact factor: 91.245

10.  Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group.

Authors:  Lisa Pleyer; Hartmut Döhner; Hervé Dombret; John F Seymour; Andre C Schuh; C L Beach; Arlene S Swern; Sonja Burgstaller; Reinhard Stauder; Michael Girschikofsky; Heinz Sill; Konstantin Schlick; Josef Thaler; Britta Halter; Sigrid Machherndl Spandl; Armin Zebisch; Angelika Pichler; Michael Pfeilstöcker; Eva M Autzinger; Alois Lang; Klaus Geissler; Daniela Voskova; Wolfgang R Sperr; Sabine Hojas; Inga M Rogulj; Johannes Andel; Richard Greil
Journal:  Int J Mol Sci       Date:  2017-02-15       Impact factor: 5.923
View more
  4 in total

1.  Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.

Authors:  C D DiNardo; I S Tiong; A Quaglieri; S MacRaild; S Loghavi; F C Brown; R Thijssen; G Pomilio; A Ivey; J M Salmon; C Glytsou; S A Fleming; Q Zhang; H Ma; K P Patel; S M Kornblau; Z Xu; C C Chua; Xufeng Chen; P Blombery; C Flensburg; N Cummings; I Aifantis; H Kantarjian; D C S Huang; A W Roberts; I J Majewski; M Konopleva; A H Wei
Journal:  Blood       Date:  2020-03-12       Impact factor: 22.113

2.  Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens.

Authors:  Curtis A Lachowiez; Sanam Loghavi; Tapan M Kadia; Naval Daver; Gautam Borthakur; Naveen Pemmaraju; Kiran Naqvi; Yesid Alvarado; Musa Yilmaz; Nicholas Short; Maro Ohanian; Sherry R Pierce; Keyur P Patel; Wei Qiao; Jing Ning; Koji Sasaki; Koichi Takahashi; Elias Jabbour; Michael Andreeff; Farhad Ravandi; Hagop M Kantarjian; Marina Konopleva; Courtney D DiNardo
Journal:  Blood Adv       Date:  2020-04-14

3.  NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy.

Authors:  Guillermo Montalban-Bravo; Rashmi Kanagal-Shamanna; Koji Sasaki; Keyur Patel; Irene Ganan-Gomez; Elias Jabbour; Tapan Kadia; Farhad Ravandi; Courtney DiNardo; Gautham Borthakur; Koichi Takahashi; Marina Konopleva; Rami S Komrokji; Amy DeZern; Teodora Kuzmanovic; Jaroslaw Maciejewski; Sherry Pierce; Simona Colla; Mikkael A Sekeres; Hagop Kantarjian; Carlos Bueso-Ramos; Guillermo Garcia-Manero
Journal:  Blood Adv       Date:  2019-03-26

Review 4.  Minimal/Measurable Residual Disease Monitoring in NPM1-Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and Perspectives.

Authors:  Fabio Forghieri; Patrizia Comoli; Roberto Marasca; Leonardo Potenza; Mario Luppi
Journal:  Int J Mol Sci       Date:  2018-11-06       Impact factor: 5.923
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.